KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Operating Expenses (2016 - 2025)

Charles River Laboratories International has reported Operating Expenses over the past 17 years, most recently at $196.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses changed 0.22% year-over-year to $196.1 million; the TTM value through Dec 2025 reached $743.1 million, down 1.06%, while the annual FY2025 figure was $743.1 million, 1.06% down from the prior year.
  • Operating Expenses for Q4 2025 was $196.1 million at Charles River Laboratories International, up from $177.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $199.8 million in Q3 2023 and troughed at $131.7 million in Q2 2022.
  • A 5-year average of $176.3 million and a median of $177.7 million in 2025 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: dropped 23.2% in 2022 and later skyrocketed 51.66% in 2023.
  • Year by year, Operating Expenses stood at $144.1 million in 2021, then skyrocketed by 38.53% to $199.6 million in 2022, then dropped by 1.25% to $197.1 million in 2023, then decreased by 0.73% to $195.7 million in 2024, then rose by 0.22% to $196.1 million in 2025.
  • Business Quant data shows Operating Expenses for CRL at $196.1 million in Q4 2025, $177.6 million in Q3 2025, and $191.5 million in Q2 2025.